Loading
companiesCompany
Outcomes4Me
Outcomes4Me is a free app that turns official cancer treatment guidelines into plain language options for each patient, and also tracks symptoms, explains genetic tests and finds clinical trials.
Overview
Outcomes4Me is a direct to patient cancer navigation platform. Its app maps a patient's diagnosis and biomarkers against NCCN Guidelines to show guideline concordant treatment options, and adds symptom and medication tracking, clinical trial matching, genetic testing education and moderated communities across more than a dozen cancer types including breast, prostate, lung, colorectal, bladder, CLL, ovarian and multiple myeloma. It reports more than 400,000 patients supported and seven of the top ten oncology pharmaceutical companies as customers, and in 2025 to 2026 acquired Mika Health, Geno.Me and the AI trial matching company Realyze Intelligence. Founded in 2017 by Maya Said and based in Boston, Outcomes4Me raised USD 4.7 million in 2020, a USD 12 million Series A led by Northpond Ventures in 2021 and USD 21 million led by Salica Investments in May 2025, for USD 38 million in total.
Headquarters
Boston, MA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Round not named by the company; labelled Series B here because it followed the 2021 Series A. Led by Salica Investments; total raised to date USD 38 million | 2025 | $21M | outcomes4me.com |
| Series A · Led by Northpond Ventures | 2021 | $12M | outcomes4me.com |
| Seed · Round not named by the company; led by Asset Management Ventures and included National Cancer Institute federal funds | 2020 | $5M | outcomes4me.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Founded
2017
Notes
top- The 2020 and 2025 rounds were not given series names by the company; Seed and Series B labels are inferred from sequence and flagged in the round notes. Website homepage was fetched via WebFetch only (curl returned a Cloudflare 403).
Similar pages
- IdeaOncology teams order germline tests; tele-genetic counsellors handle the results
Shares Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- CompanyStrata Oncology
Shares AI trial matching & clinical decision support, Colorectal cancer, Non-small-cell lung cancer.
- InstitutionUniversity of Malaya Medical Centre
Shares Germline (hereditary) testing, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Colorectal cancer.
- InstitutionTohoku University Hospital
Shares Germline (hereditary) testing, HR-positive / HER2-negative breast cancer, Colorectal cancer, Non-small-cell lung cancer.
- Key paperFounder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer
Shares Germline (hereditary) testing, Ovarian cancer, Triple-negative breast cancer (TNBC).
- InstitutionInstituto Português de Oncologia do Porto Francisco Gentil
Shares Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer, Prostate cancer.
- IdeaPopulation germline screening for hereditary cancer genes with cascade testing
Shares Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- Key paperTailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer
Shares Germline (hereditary) testing, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.